Sat, Oct 25, 2014, 11:32 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • galaberge galaberge Mar 25, 2013 7:19 AM Flag

    "The consistently strong results of the two Phase 3 studies support the promise of tedizolid as a safe and effective new antibiotic, especia

    "These results confirm Trius' ability to successfully execute a comprehensive clinical program intended to support global approval," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius. "We are committed to responding to the needs of patients and physicians worldwide for new and effective antibiotics. Looking ahead, we intend to file our NDA for tedizolid as well as initiate a Phase 3 study of tedizolid in patients with severe pneumonia during the second half of this year."

    Sentiment: Strong Buy

 
TSRX
13.630.00(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.